Harpreet Singh has joined Precision for Medicine, a clinical research organization, as chief medical officer. In her new role, Singh, a former division director of oncology at FDA, will be responsible for medical strategy and oversight.
As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments. Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...
